U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167446) titled 'Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy' on Aug. 27.
Brief Summary: This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
Study Start Date: Sept. 05
Study Type: INTERVENTIONAL
Condition:
Oxaliplatin Induced Perip...